(Reuters) – Swiss drug maker Actelion’s chief executive quashed speculation over its possible interest in purchasing Basilea Pharmaceutica.
“Basilea has developed interesting medications. But the company already has a partner,” Chief Executive Jean-Paul Clozel was quoted as saying in an interview published on Swiss paper Finanz und Wirtschaft’s website on Friday.
“Since we’re interested in active substances and not financial opportunities, it wouldn’t make sense for us to buy Basilea.”
(Reporting by Brenna Hughes Neghaiwi)
The deal inked with New York-based Ovid Therapeutics carries an almost $200 million upfront payment and could be worth as much as $856 million provided the medicine, known as soticlestat, hits certain milestones.
Novartis has entered an initial agreement to manufacture the mRNA and bulk drug product for CureVac’s Covid-19 vaccine candidate, CVnCoV.
A whole new world: Philips and the Walt Disney Company will use animated shorts featuring some of Disney’s most famous characters in customized stories created with clinical guidance from Philips.
